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Background: Intrauterine growth restriction (IUGR) is a 
major risk factor for both perinatal and long-term morbidity. 
Bovine lactoferrin (bLf ) is a major milk glycoprotein considered 
as a  pleiotropic functional nutrient. The impact of maternal 
supplementation with bLf on IUGR-induced sequelae, includ-
ing inadequate growth and altered cerebral development, 
remains unknown.
Methods: IUGR was induced through maternal dexa-
methasone infusion (100 μg/kg during last gestational week) 
in rats. Maternal supplementation with bLf (0.85% in food 
pellet) was provided during both gestation and lactation. 
Pups growth was monitored, and pup brain metabolism and 
gene expression were studied using in vivo 1H NMR spectros-
copy, quantitative PCR, and microarray in the hippocampus 
at postnatal day (PND)7.
results: Maternal bLf supplementation did not change ges-
tational weight but increased the birth body weight of control 
pup (4%) with no effect on the IUGR pups. Maternal bLf supple-
mentation allowed IUGR pups to recover a normalized weight 
at PND21 (weaning) improving catch-up growth. Significantly 
altered levels of brain metabolites (γ-aminobutyric acid, gluta-
mate, N-acetylaspartate, and N-acetylaspartylglutamate) and 
transcripts (brain-derived neurotrophic factor (BDNF), divalent 
metal transporter 1 (DMT-1), and glutamate receptors) in IUGR 
pups were normalized with maternal bLf supplementation.
conclusion: Our data suggest that maternal bLf supple-
mentation is a beneficial nutritional intervention able to revert 
some of the IUGR-induced sequelae, including brain hippo-
campal changes.
intrauterine growth restriction (IUGR) leads to low birth weight, an important predictor of mortality and morbidity in the new-
born (1). However, IUGR is not only associated with an increased 
risk in perinatal mortality but also with a higher prevalence of 
developing diseases/disabilities later in life (2). This “fetal origin 
of adult diseases” hypothesis proposes that an impaired intra-
uterine environment (e.g., deficient in nutrients, oxygen, hor-
mones, or enriched in toxics), leading to abnormal fetal growth 
and altered tissue development programs the fetus for later 
chronic diseases in adulthood (2). Although cerebral structures 
are more preserved than other tissues during deleterious condi-
tions of growth (brain sparing effect), IUGR also  compromises 
brain development and increases the risk for later mental and 
psychomotor developmental complications, in particular in 
infants not showing catch-up growth (3). The hippocampus 
appears to be especially susceptible to the effects of IUGR, as 
well as in animal models (4) as in the human situation (5). Many 
experimental models of IUGR, involving maternal restriction in 
nutrients, exposure to hypoxia/ischemia or limitation in blood 
supply, have allowed elucidating some mechanisms involved in 
this deleterious “programming” process. In utero exposure to 
synthetic glucocorticoids is another experimental animal model 
of IUGR, mimicking maternal stress. Clinically, glucocorticoids 
are also administered to pregnant women with risk of premature 
delivery. By enhancing fetal lung maturation, this antenatal treat-
ment presents an immediate benefit for  preterm neonate survival 
but long-term consequences of repeated doses of antenatal glu-
cocorticoid include alterations in growth and brain development 
(6). Rodent studies also showed that antenatal glucocorticoid 
exposure predisposes the offspring to early glucose intolerance 
(7) and disturbed cerebral development (8).
The impact of nutrition in early life on neurodevelopment 
is a major field of investigation but also a controversial topic 
due to the complexity of dissociating genetic, environmental, 
and nutritional influences. However, nutrients naturally pres-
ent in milk may represent the most appropriate candidates to 
safely improve early brain development, particularly following 
adverse prenatal conditions. Lactoferrin (Lf) is a glycoprotein 
whose highest levels are found in colostrum and in mature milk 
(9). Lf exhibits pleiotropic biological properties, such as a role 
in iron homeostasis, in the immune response, in the prevention 
of tumorigenesis, as well as in anti-inflammatory processes (for 
review, see ref. 10). Interestingly, this functional nutrient was 
recently shown to reduce the incidence of late-onset bacterial 
and fungal sepsis in low-birth-weight neonates (11). Lf is also 
produced in the brain (12) and its upregulation in the central 
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nervous system during neurodegenerative disorders and aging 
(13) suggests an endogenous neuroprotecting mechanism. 
Interestingly, exogenous Lf, such as dietary bovine lactofer-
rin (bLf) ingested with food, is relatively resistant to digestive 
degradation and is actively transported into the brain (14). 
Little knowledge about bLf nutritional supplementation during 
gestation, both on maternal parameters and pup development 
(including brain), is presently available. The main objective of 
our study was to assess the effect of maternal bLf nutritional 
supplementation (0.85% in food pellet) in a dexamethasone-
induced IUGR rat model, with special focus on pup growth and 
early brain metabolism/gene expression in the hippocampus.
RESULTS
Effect of Nutritional bLf Supplementation on Maternal 
Weight Gain and Hematological Values During Normal and 
Dexamethasone (DEX)-Exposed Gestation
To evaluate whether a 0.85% (w/w) bLf nutritional supple-
mentation grossly affects maternal physiology, we  monitored 
weight gain and blood values in gestating dams. Dual ges-
tational subcutaneous DEX infusion and nutritional bLf 
supplementation resulted in four groups of animals stud-
ied in parallel: CONTROL (vehicle infusion/maternal nor-
mal diet), DEX (dexamethasone infusion/maternal normal 
diet), LACTO (vehicle infusion/maternal bLf-enriched diet), 
and DEX+LACTO (dexamethasone infusion/maternal bLf-
enriched diet) (Figure 1). Maternal body weight throughout 
gestation (Figure 2a) as well as weight gain during the third 
Figure 1. Study experimental groups. The four treatment groups 
(CONTROL, DEX, LACTO, and DEX+LACTO) of gestating/lactating rats 
resulting from different subcutaneous (s.c.) infusions (vehicle or dexa-
methasone (DEX)) and food pellets provided (normal or bLf-enriched).  
The number refers to gestational or postnatal age in days. bLf, bovine 
lactoferrin; G, gestational day; PND, postnatal day.
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Figure 2. Maternal weight and food intake in dexamethasone (DEX)-exposed and control dams fed with bLf-enriched or normal diet. (a) Maternal body 
weight curve during gestation, *P < 0.001 vs. CONTROL. (b) Body weight gain, *P < 0.01 vs. CONTROL. (c) Food intake, *P < 0.01 vs. CONTROL. (d) Food 
efficiency, *P < 0.01 vs. CONTROL. Panels b, c, d represent data collected during the third week of gestation (G14-21) corresponding to dexamethasone 
exposure. Results are means ± SEM of N = 16–21 gestating dams per group. b.w. body weight; C, CONTROL group (white bar); D, DEX group (light grey 
bar); D+L, DEX and LACTO group (dark grey bar); L, LACTO group (black bar).
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week of gestation (Figure 2b) was significantly decreased with 
dexamethasone exposure, but no counteracting effect of bLf 
nutritional supplementation was found. During the first 2 wk 
of gestation (G0-G14), food intake was the same in four groups 
of animals, excluding an impact of bLf supply on this param-
eter (data not shown). Cumulative food intake during the 
third week of gestation was significantly reduced in DEX dams 
(Figure 2c). DEX+LACTO dams present a trend to increase 
their food intake (Figure 2c). Food efficiency (weigh gain 
reported to amount of food intake) was not influenced by bLf 
but was drastically reduced both in DEX and DEX+LACTO 
dams (Figure 2d).
Since bLf is known to act both as a maturation factor 
for immune cells and a regulator for iron homeostasis, we 
analyzed white blood cell content, lymphocyte content, red 
blood cell content, hemoglobin levels (Hb), hematocrit, and 
platelet levels in dams (Table 1). Measurements were done at 
gestational day (G) 0, G14 (2 wk following bLf supplementa-
tion start/before DEX exposure) and at G21 (3 wk following 
bLf supplementation start/after 1 wk of DEX exposure). bLf 
supplementation slightly increased circulating immune cells 
(without attenuating the immunosuppressive action of DEX) 
with no effect on hematocrit, red blood cell, and Hb content 
(Table 1).
Litter Characteristics and Body Weight of Offspring at Birth
No difference was observed in the sex ratio of newborn 
pups within the CONTROL, DEX, and DEX+LACTO litters 
(Figure  3a, inside bar, F = female, M = male). A slight ran-
dom increase in female proportion (P = 0.03) was observed 
in LACTO litters compared to CONTROL litters. The num-
ber of pups per litter was not statistically different in the 
LACTO group (P = 0.71) compared to the CONTROL group. 
Smaller litters were similarly observed in both the DEX and 
DEX+LACTO groups (P < 0.01 vs. CONTROL; Figure 3a). 
On postnatal day (PND)1, body weight of LACTO pups was 
significantly higher (≈4%) compared to CONTROL pups 
(P < 0.001; Figure 3b,c). As expected, on PND1, weight of DEX 
pups was decreased compared to respective CONTROL ani-
mals (P < 0.00001; Figure 3b,c). Maternal bLf supplementation 
during gestation had no effect on DEX-induced IUGR phe-
notype since PND1 body weight of DEX+LACTO pups were 
not different to those of respective DEX pups (Figure 3b,c). 
These observations confirm the IUGR phenotype of DEX pups, 
clearly demonstrate an 4% increase in PND1 weight of pups 
table 1. Hematological values in gestating rats
Gestational day
BASAL CONTROL DEX LACTO DEX+LACTO
G0 G14 G21 G14 G21 G14 G21 G14 G21
White blood cells (×103/µl) 11.4 ± 0.4 10.0 ± 0.7 10.6 ± 1.3 10.4 ± 0.9 7.2 ± 0.6*,a,b 11.8 ± 0.7 11.1 ± 09 11.1 ± 0.9 7.6 ± 0.5*,b
Lymphocytes (×103/µl) 8.6 ± 0.3 7.3 ± 0.5* 6.1 ± 0.8* 7.3 ± 0.7 1.5 ± 0.3*,a,b 8.4 ± 0.6 6.3 ± 0.6*,b 8.0 ± 1.0 1.9 ± 0.4*,b
Red blood cells (×106/µl) 7.1 ± 0.1 6.8 ± 0.2 5.6 ± 0.4*,b 6.7 ± 0.2* 6.6 ± 0.2a 6.8 ± 0.2 5.1 ± 0.4*,b 6.7 ± 0.3 6.2 ± 0.4*
Hemoglobin (g/dl) 14.3 ± 0.3 13.7 ± 0.2 10.7 ± 0.6*,b 13.6 ± 0.5 13.0 ± 0.4*,a 13.3 ± 0.4* 10.2 ± 0.8*,b 13.6 ± 0.5 12.0 ± 0.6*
Hematocrit (%) 41.1 ± 0.8 39.1 ± 1.1 31.3 ± 2.0*,b 38.5 ± 1.3 37.9 ± 1.5*,a 39.0 ± 1.3 29.0 ± 2.4*,b 38.6 ± 1.5 35.6 ± 2.0*
Platelet (×103/µl) 806 ± 42 908 ± 41 1,333 ± 78*,b 920 ± 63 959 ± 65a 929 ± 52 1,105 ± 92* 997 ± 46* 986 ± 65*
all values represent mean ± SeM of N = 8–12 animals per group.
G, gestational day.
*P < 0.05 compared to BaSaL G0.
aP < 0.05 for DeX G21 vs. CONTROL G21. bP < 0.05 for G21 vs. G14 in the same group.
Figure 3. Litter size, sex ratio, and perinatal body weight of pups born to 
dexamethasone (DEX)-exposed and control dams fed with bLf-enriched 
or normal diet. (a) Number of pups per litter. Results are means ± SEM. N = 
16–21 litters per group. *P < 0.001 vs. CONTROL. Inside bar: F, female; M, male. 
The day 1 body weight of (b) male and (c) female pups. Results are means 
± SEM. N = 109–125 pups per group (panel b), N = 99–128 pups per group 
(panel c). *P < 0.001 vs. CONTROL and †P < 0.001 vs. CONTROL. The day 21 
body weight (weaning weight) of (d) male and (e) female pups. Results are 
means ± SEM. N = 35–60 pups per group (panel d), N = 38–45 pups per group 
(panel e). *P < 0.001 vs. CONTROL and §P < 0.001 vs. DEX. Note the catch-up 
of DEX+LACTO pups compared to DEX pups in panels d and e. b.w. body 
weight; C, CONTROL group (white bar); D, DEX group (light grey bar); D+L, 
DEX and LACTO group (dark grey bar); L, LACTO group (black bar).
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from bLf-supplemented dams, and show no effect of maternal 
bLf supplementation during gestation on IUGR phenotype of 
DEX pups at birth.
Early Postnatal Growth of Offspring Until Weaning
Monitoring of pup weight during the lactating period showed 
that despite initial differences, weight of LACTO pups was 
similar to that of the respective CONTROL pups at weaning 
(PND21) (Figure 3d,e). DEX pups remain lighter than the 
respective CONTROL animals (P < 0.0002 vs. CONTROL; 
Figure 3d,e). DEX+LACTO animals start a catch-up during 
the second week of life. At PND21, weight of DEX+LACTO 
pups was similar to that of the respective CONTROL animals 
(Figure 3d,e), suggesting that maternal nutritional bLf sup-
plementation during lactation allowed to improve the DEX-
induced IUGR phenotype.
Neurochemical Profile and Gene Expression in the Hippocampus
We investigated pup hippocampal metabolism and gene 
expression using both noninvasive in vivo approaches 
(1H NMR spectroscopy) and classical ex vivo methods 
(real-time quantitative PCR and microarray). We focused our 
attention on the study of hippocampus at PND7 (a signifi-
cant time point corresponding to a late neuronal proliferative 
phase) since this brain limbic region involved in the long-term 
memory process contains high levels of glucocorticoid recep-
tors, making it particularly vulnerable to DEX-induced fetal 
programming (8,15).
Magnetic resonance imaging showing the voxel of interest 
used to acquisition of the spectra is illustrated in Figure 4a. 
Interestingly, hippocampal levels of γ-aminobutyric acid 
(P < 0.05), glutamate (Glu) (P < 0.03), N-acetylaspartate (NAA) 
(P < 0.001), N-acetylaspartylglutamate (NAAG) (P < 0.01), all 
decreased in DEX-IUGR pups, were partially or fully normal-
ized in DEX+LACTO pups (Figure 4b). The same recovery 
from DEX-altered neurochemical profile through maternal 
bLf supplementation was observed for hippocampal pools of 
NAA+NAAG and Glu+Gln (Figure 4b). Among the other 
numerous metabolites consistently quantified from NMR 
spectra, no change was detected for macromolecules, ascor-
bate, aspartate, phosphocholine, creatine (Cr), glucose, gluta-
mine, glutathione, inositol, phosphoethanolamine, or taurine 
(data not shown).
The hippocampal mRNA levels of selected genes involved 
in neurodevelopment were also assessed on PND7 to 
 corroborate metabolic neurochemistry to specific transcrip-
tional changes. Among the various transcripts screened, 
brain-derived  neurotrophic factor (BDNF) and divalent metal 
transporter 1 (DMT-1) presented a downexpression in the 
DEX pups (P < 0.02 vs. CONTROL) which is normalized in 
Figure 4. Hippocampus characterization of pups born to dexamethasone (DEX)-exposed and control dams fed with bLf-enriched or normal diet. 
(a) Position of the voxel of interest for hippocampus 1H-MRS and typical spectra of the hippocampus of a CONTROL PND7 pup, (b) metabolite concentra-
tions, (c) gene expression, and (d) representative cell density of the hippocampus at PND7. Results are means ± SEM of N = 5–8 pups per group (b), N = 10 
pups per group (c). *P < 0.05 vs. CONTROL, †P < 0.05 vs. CONTROL and § P < 0.05 vs. DEX. Abbreviations and color code: C, CONTROL group (white bar); D, 
DEX group (light grey bar); L, LACTO group (black bar); D+L, DEX and LACTO group (dark grey bar). AU, arbitrary units.
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DEX+LACTO pups (Figure 4c). Staining of hippocampal slices 
with 4′-6-Diamidino-2-phenylindole (Figure 4d) revealed 
that molecular and transcriptional changes observed in DEX-
IUGR pups lead or reflect a reduced neuronal density. Once 
again, DEX+LACTO pups appeared similar to CONTROL 
pups for this endpoint (Figure 4d). To further character-
ize transcriptional changes occurring in the pup developing 
hippocampus, microarray analyses were performed among 
the different animal groups. We only considered array gene 
expression changes greater than 20%, with a P value < 0.001 
(Tables 2 and 3) and validated some of them by real-time quan-
titative PCR (Figure 5). Transcripts upregulated in DEX pups 
compared to CONTROL pups belong to the iron-containing 
oxygen-transport metalloprotein  family (Hba-a2, Hbb), to the 
glutamate signaling and transport pathway (Grm2, Slc1a3) or 
present neuromodulator functions (Ptgds, Ptn). Gene expres-
sion of several transcripts required for a normal cerebral devel-
opment was downregulated in DEX pups (Plxna2, Ncam1, 
Dpysl3, Gsk3b, Lsamp, Prkce, Nfix, Crim1, Map1b, Pi4k2a, 
and Dynlt3). Several neuromodulator transcripts of interest 
were upregulated in LACTO compared to CONTROL pups: 
Enc1, Ttr, Plp1, Metrn, Ptma, and Clu. Some of them were 
also overexpressed in the DEX+LACTO vs. DEX group (Enc1, 
Metrn, and Ptma). Other transcripts were specifically upregu-
lated in the DEX+LACTO vs. DEX group, such as Nrep, Dhps, 
and S100b. Transcripts for various glutamate receptors (Grm2, 
Grin1, and Grin2a) were downregulated in the DEX+LACTO 
vs. DEX group. Other neuromodulator transcripts present a 
specific downregulation in the DEX+LACTO vs. DEX group 
(Dscam, Pard3, and egr1). Gene expression of four genes per 
comparison (DEX vs. CON (Figure 5a), LACTO vs. CON 
(Figure 5b), and DEX+LACTO vs. DEX (Figure 5c)) were 
investigated using real-time quantitative PCR and confirmed a 
significant change or a clear trend. The correlation between the 
fold changes observed with the microarray and the real-time 
quantitative PCR experiment was high, R = 0.88, P < 0.001 
(Figure 5d). Together, these observations show that DEX-
IUGR hippocampus present specific transcriptional alterations 
partially reverted with maternal bLf supplementation.
DISCUSSION
In the present study, we evaluated the potentially protective 
action of bLf, a glycoprotein with pleiotropic actions, on DEX-
induced IUGR sequelae, on pup somatic growth and with 
special focus on brain hippocampus metabolism and gene 
expression.
The nutritional supplementation with bLf showed no effect 
on maternal weight gain both during normal and DEX-altered 
gestation. A gestational window of bLf supplementation also 
failed to improve the low-birth-weight phenotype of DEX pups 
but significantly increased by 4% the birth weight of control 
pups, without any change in litter size, indicating a primary 
antenatal anabolic action of this nutrient.
Postnatally, DEX-IUGR pups remained lighter than control 
animals until weaning (PND21), as previously reported (7). 
Maternal supplementation with bLf during lactation resulted 
in different effects compared to the gestational period. Despite 
initial higher birth weights, maternally bLf-exposed pups grew 
similarly to control pups until PND21. Interestingly, DEX-
induced IUGR pups from bLf-supplemented dams started a 
catch-up growth during the second week of life and showed 
a total body weight recovery at PND21. Even if underlying 
mechanisms involved in this catch-up process remain to be 
elucidated, this observation represents to our knowledge one 
of the first nutritional intervention able to correct growth in 
IUGR without overfeeding involving, for example, litter size 
reduction. Enhanced growth performance has been reported 
in ICR mice pups from transgenic dams harboring a por-
cine Lf gene expressed in the mammary gland (16). Maternal 
bLf supply could act on pup growth, indirectly through dam 
effects impacting blood or milk composition, or directly fol-
lowing a placental/milk transfer. Some anabolic functions of 
bLf have previously been reported such as activation of hepatic 
protein synthesis (17) or improved intestinal function (18). 
These present rodent observations could be clinically relevant 
since the highest concentration of Lf is found in colostrum (9) 
and higher levels of Lf are found in preterm mature milk (19), 
suggesting a growth-promoting action for Lf during highly 
sensitive periods of development. Nutritional supplementa-
tion with bLf or recombinant Lf could be of great interest to 
enhance growth in low-birth-weight babies, in addition to its 
interesting protective effects against sepsis in this frail popu-
lation (11). The dose presently provided to dams (0.85% w/w 
in the food pellet) results in a consumption of ~500–1,300 mg 
bLf/kg of body weight per day, depending on the period 
 (gestation/lactation) considered. This amount is relatively 
high but provides no supplemental energy intake since it was 
replaced by isocaloric amount of casein in control food. More 
work is needed to determine whether bLf presents a dose–
response action and whether early bLf exposition allows sym-
metrical catch-up growth, including a proportional gain of 
lean, fat, and bone mass. In this sense, the activator effects of 
bLf on osteoblasts in rodents (20) and the presence of endog-
enous Lf during the early phases of the human endochondral 
ossification (21) suggest that Lf harbors a bone-promoting 
action whereas its effects on adipogenesis remain more elu-
sive (22,23).
Beyond somatic growth, IUGR also impacts brain develop-
ment, thus increasing the risk for later neurological compli-
cations (24). In the present study, we focused our attention 
on brain hippocampal metabolism and gene expression at 
PND7, a late neuronal proliferative phase in the rat, docu-
menting for the first time alterations of this tissular develop-
ment due to DEX-induced IUGR and the potential reversal of 
these alterations by bLf supplementation. This cerebral part 
of the limbic system, expressing high levels of glucocorti-
coid receptors early in life (25) is particularly alterable in the 
human IUGR situation (5) as well as in DEX-induced IUGR 
animal models (8,15).
The neurochemical profile detected by high-field 1H 
NMR spectroscopy (9.4T) allows to noninvasively measure 
the levels of numerous metabolites reflecting structural 
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table 2. Transcriptional upregulations in the developing 
hippocampus at postnatal day 7
Fold change Symbol Definition
deX vs. con (upregulated)
Iron-containing oxygen-transport 
metalloprotein family
2.08 LOC287167 Globin, α (LOC287167), mRNA
1.54 MGC72973 β-glo (MGC72973), mRNA
1.51 Eraf Erythroid-associated factor (predicted), 
mRNA
1.45 Hba-a2 Hemoglobin α, adult chain 2 (Hba-a2), 
mRNA
1.42 Hbb Hemoglobin β chain complex (Hbb), 
mRNA
1.37 F2r Coagulation factor II (thrombin) 
receptor (F2r), mRNA
Detoxication pathway during drug 
metabolism
1.62 RGD1561381 Microsomal glutathione S-transferase 3 
(predicted), mRNA
1.33 Pex11b Peroxisomal biogenesis factor 11b 
(Pex11b), mRNA
1.26 Txnrd1 Thioredoxin reductase 1 (Txnrd1), 
mRNA
1.24 Ephx2 Epoxide hydrolase 2, cytoplasmic 
(Ephx2), mRNA
Glutamate signaling and transport 
pathway
1.32 Grm2 Glutamate receptor, metabotropic 2 
(Grm2), mRNA
1.31 Slc1a3 Glial high-affinity glutamate 
transporter, member 3 (Slc1a3), mRNA
Neuromodulator
1.32 Ptn Pleiotrophin (Ptn), mRNA
1.31 Ptgds Prostaglandin D2 synthase (brain) 
(Ptgds), mRNA
1.27 GIPR Gastric inhibitory polypeptide receptor 
(Gipr), mRNA
1.23 Vip Vasoactive intestinal polypeptide (Vip), 
mRNA
1.20 Rgs4 Regulator of G-protein signaling 4 
(Rgs4), mRNA
Cellular morphology and assembly or 
reconnaissance pathway
1.38 Gsn Gelsolin (Gsn), mRNA
1.24 Krt19 Keratin 19 (Krt19), mRNA
1.24 Cadm1 Cell adhesion molecule 1 (Cadm1), 
mRNA
1.21 Gjb2 Gap junction protein, β 2 (Gjb2), mRNA
1.21 Mrlcb Myosin light chain, regulatory B (Mrlcb), 
mRNA
lacto vs. con (upregulated)
Neuromodulator
1.74 Ptgds Prostaglandin D2 synthase (brain) 
(Ptgds), mRNA
1.47 Enc1 Ectodermal-neural cortex 1 (Enc1), 
mRNA
1.23 Ptma Prothymosin α (Ptma), mRNA
1.23 Metrn Meteorin, glial cell differentiation 
regulator (Metrn), mRNA
1.23 Clu Clusterin (Clu), mRNA
1.23 Id2 Inhibitor of DNA binding 2 (Id2),  
mRNA
Cellular morphology and assembly or 
reconnaissance pathway
1.51 Eml2 Echinoderm microtubule associated 
protein like 2 (Eml2), mRNA
1.30 Necab2 N-terminal EF-hand calcium binding 
protein 2 (Necab2), mRNA
1.27 Tpm4 Tropomyosin 4 (Tpm4), mRNA
1.27 Cldn5 Claudin 5 (Cldn5), mRNA
1.26 Plp1 Proteolipid protein 1 (Plp1), mRNA
1.23 Tagln2 Transgelin 2 (Tagln2), mRNA
1.21 Tm7sf2 Transmembrane 7 superfamily member 
2 (Tm7sf2), mRNA
1.20 Asb2 Ankyrin repeat and SOCS box-
containing 2 (Asb2), mRNA
1.20 Pigy Phosphatidylinositol glycan anchor 
biosynthesis, class Y (Pigy), mRNA
1.20 Tuba4a Tubulin, α 4A (Tuba4a), mRNA
Nutritional marker
1.28 Ttr Transthyretin (Ttr), mRNA
1.23 Alb Albumin (Alb), mRNA
deX+lacto vs. deX (upregulated)
Neuromodulator
1.45 Enc1 Ectodermal-neural cortex 1 (Enc1), 
mRNA
1.30 Metrn Meteorin, glial cell differentiation 
regulator (Metrn), mRNA
1.26 Ptma Prothymosin α (Ptma), mRNA
1.24 Nrep Neuronal regeneration related protein 
(Nrep), mRNA
1.23 S100b S100 calcium binding protein B (S100b), 
mRNA
1.21 Dhps Deoxyhypusine synthase (Dhps),  
mRNA
Cellular morphology and assembly or 
reconnaissance pathway
1.41 LOC689827 Myosin-9B (myosin IXb) 
(unconventional myosin-9b), mRNA
1.41 Argbp2 Arg/Abl-interacting protein ArgBP2 
(Argbp2), mRNA
1.28 Dynlrb2 Dynein light chain roadblock-type 2 
(predicted), mRNA
1.27 Dnah1 Dynein, axonemal, heavy chain 1 
(Dnah1), mRNA
1.25 Canx Calnexin (Canx), mRNA
1.23 Tpm4 Tropomyosin 4 (Tpm4), mRNA
1.21 Ctnnb1 Catenin (cadherin associated protein), β 
1 (Ctnnb1), mRNA
1.21 Tekt1 Tektin 1 (Tekt1), mRNA
table 2. Continued
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and functional characteristics of selected cerebral regions. 
Interestingly, we observed that hippocampal levels of excit-
atory (glutamate) and inhibitory (γ-aminobutyric acid) 
neurotransmitters and neuronal markers (NAA) were sig-
nificantly decreased in DEX-induced IUGR pups and were 
partially or fully normalized with maternal bLf supply. BDNF 
gene expression strikingly followed the same regulation pat-
tern. These results, corroborated by our histological obser-
vations, suggest that neuronal density in the hippocampus 
is dampened in DEX-induced IUGR pups but normalized 
with maternal bLf supply. Previous studies also report BDNF 
downregulation by synthetic corticoids. In vivo, direct 
table 3. Transcriptional downregulations in the developing 
hippocampus at PND7
Fold 
change Symbol Definition
deX vs. con (downregulated)
Cell migration/axonal guidance/neurite 
outgrowth
0.81 Ncam1 Neural cell adhesion molecule 1 (Ncam1), 
mRNA
0.80 Plxna2 Plexin A2 (predicted), mRNA
0.80 Gsk3b Glycogen synthase kinase 3 β (Gsk3b), 
mRNA
0.78 Lsamp Limbic system-associated membrane 
protein (Lsamp), mRNA
0.75 Prkce Protein kinase C, epsilon (Prkce), mRNA
0.72 Dpysl3 Dihydropyrimidinase-like 3 (Dpysl3), mRNA
Neuromodulator
0.79 Crim1 Cysteine-rich motor neuron 1 (predicted), 
mRNA
0.78 Appbp2 Amyloid β precursor protein binding 
protein 2 (Appbp2), mRNA
0.76 Nfix Nuclear factor I/X (Nfix), mRNA
0.72 Cnr1 Cannabinoid receptor 1 (brain) (Cnr1), 
mRNA
Cellular morphology and assembly or 
reconnaissance pathway
0.78 Pi4k2a Phosphatidylinositol 4-kinase type 2 α 
(Pi4k2a), mRNA
0.73 Map1b Microtubule-associated protein 1b 
(Map1b), mRNA
0.72 Dynlt3 Dynein light chain Tctex-type 3 (Dynlt3), 
mRNA
0.70 Plekhf2 Pleckstrin homology domain containing, 
family F member 2 (predicted), mRNA
0.70 Argbp2 Arg/Abl-interacting protein ArgBP2 
(Argbp2), mRNA
lacto vs. con (downregulated)
Gene expression regulator
0.79 Bat1 HLA-B associated transcript 1 (Bat1), mRNA
0.76 Hdac4 Histone deacetylase 4 (predicted), mRNA
0.73 Hdac5 Histone deacetylase 5 (Hdac5), mRNA
Thyroid metabolism
0.65 Thrb Thyroid hormone receptor β (Thrb), mRNA
deX+lacto vs. deX (downregulated)
Thyroid metabolism
0.76 Klf9 Kruppel-like factor 9 (Klf9), mRNA
0.61 Thrb Thyroid hormone receptor β (Thrb), mRNA
Detoxication pathway during drug 
metabolism
0.64 Ephx2 Epoxide hydrolase 2, cytoplasmic (Ephx2), 
mRNA
0.44 RGD1561381 Microsomal glutathione S-transferase 3 
(predicted), mRNA
Glutamate signaling and transport 
pathway
0.81 Grin2a Glutamate receptor, ionotropic, N-methyl 
D-aspartate 2A (Grin2a), mRNA
0.80 Grin1 Glutamate receptor, ionotropic, N-methyl 
D-aspartate 1 (Grin1), mRNA
0.79 Slc1a3 Glial high affinity glutamate transporter, 
member 3 (Slc1a3), mRNA
0.78 Grm2 Glutamate receptor, metabotropic 2 
(Grm2), mRNA
Neuromodulator
0.81 Dscam Down syndrome cell adhesion molecule 
(Dscam), mRNA
0.81 Pard3 Par-3 (partitioning defective 3) 
homolog (Caenorhabditis elegans) 
(Pard3), mRNA
0.80 Gm2a GM2 ganglioside activator (Gm2a), mRNA
0.80 Egr1 Early growth response 1 (Egr1), mRNA
0.80 Synj2 Synaptojanin 2 (Synj2), mRNA
0.55 Dnmt3a DNA methyltransferase 3A (Dnmt3a), 
transcript variant 2, mRNA
Cellular morphology and assembly or 
reconnaissance pathway
0.81 Itga1 Integrin α 1 (Itga1), mRNA
0.81 Actg2 Actin, gamma 2, smooth muscle, enteric 
(Actg2), mRNA
0.80 Lgals5 Lectin, galactose binding, soluble 5 
(Lgals5), mRNA
0.80 Mmp14 Matrix metallopeptidase 14 (membrane-
inserted) (Mmp14), mRNA
0.80 Notch1 Notch gene homolog 1 (Drosophila) 
(Notch1), mRNA
0.80 Col3a1 Collagen, type III, α 1 (Col3a1), mRNA
0.77 Dync1li1 Dynein cytoplasmic 1 light intermediate 
chain 1 (Dync1li1), mRNA
0.77 Gjb6 Gap junction protein, β 6 (Gjb6), mRNA
0.76 Tagln Transgelin (Tagln), mRNA
0.76 Pkp2 Plakophilin 2 (Pkp2), mRNA
0.75 Gsn Gelsolin (Gsn), mRNA
0.75 Lox Lysyl oxidase (Lox), mRNA
0.70 Myo5a Myosin Va (Myo5a), mRNA
table 3. Continued
Fold 
change Symbol Definition
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exposure to dexamethasone was reported to decrease the 
level of BDNF mRNA in the rat hippocampus (26), and pre-
natal dexamethasone exposure blocks the stimulated BDNF 
elevation in the paraventricular nucleus (27). In the same 
way, in vitro, dexamethasone prevents activity-dependent 
increases in BDNF in rat hippocampal neurons (28) through 
different mechanisms including (i) inhibition of postsyn-
aptic Ca(2+) influx (29), (ii) inhibition of presynaptic gluta-
mate release (29) via a direct glucocorticoid receptor-BDNF 
receptor interaction (30), and (iii) blockade of the signal-
ing pathway mediating the BDNF-induced synaptic pro-
teins involved in neuron maturation (29). Both these data 
and our present results suggest that in DEX-induced IUGR 
pup hippocampus, decreased levels of BDNF and glutamate 
could potentiate each other leading to limitation in neuro-
nal development. Another cross-observation between 1H 
NMR spectroscopy results and transcriptomic approaches 
was illustrated by decreased hippocampal levels of NAAG 
(a neuromodulatory peptide expressed in neuronal 
 terminals) associated with overexpression of the presynaptic 
glutamate receptor metabotropic 2 (Grm2) in DEX-IUGR 
pups. NAAG is known to bind both presynaptic metabo-
tropic glutamate receptors Grm2/3 to limit neurotransmitter 
release (31) and postsynaptic N-methyl-D-aspartate recep-
tors with agonistic (32) or antagonistic activity (33). Once 
again, hippocampal levels of NAAG, Grm2 mRNA as well as 
N-methyl-D-aspartate receptor subunits 1 (Grin1) and 2A 
(Grin2a) mRNA were normalized with maternal bLf supple-
mentation. N-methyl-D-aspartate receptors are centrally 
involved in hippocampal synaptic plasticity (34) and seem 
to be selectively targeted in the IUGR situation. Altered 
composition of glutamate receptor subunits was recently 
observed in the hippocampus of IUGR rats born from an 
uteroplacental insufficiency model (35) and N-methyl-D-
aspartate receptor subtype 2B (Grin2b) was increased in the 
hippocampus of prenatally stressed rats (36).
Microarrays allowed us to deeper characterize the hip-
pocampal transcriptomic hallmark in DEX-IUGR pups as 
well as the impact of maternal bLf. As very subtle transcrip-
tional responses are generally observed in the brain follow-
ing experimental interventions, we considered biologically 
relevant and statistically significant gene expression changes 
greater than 20%, with a P value < 0.001. We also validated 
some microarray observations using real-time quantitative 
PCR. The  correlation between the fold changes observed 
with the microarray and with the real-time quantitative PCR 
method was high (R = 0.88; P < 0.001) although this relation 
is known to become weaker with changes below 1.5-fold (37). 
Numerous transcripts identified in the literature as required 
for normal cerebral development were downregulated in our 
Figure 5. Validation of microarray gene expression changes using real-time quantitative PCR. Hippocampus mRNA levels of selected genes (a) 
in CONTROL and DEX pups, (b) in CONTROL and LACTO pups, (c) in DEX and DEX+LACTO pups at postnatal day 7. For all panels, relative results obtained 
by real-time qPCR are expressed in arbitrary units (AU) and each bar represents the mean ± SEM of n = 10 animals per group. *P < 0.05 vs. CONTROL, †P < 
0.05 vs. CONTROL and §P < 0.05 vs. DEX. (d) Linear regression analysis of fold-change from microarray and real-time qPCR results. Correlation coefficient 
R = 0.88, P < 0.001. Enc1, ectodermal-neural cortex 1; Grin1, glutamate receptor ionotropic N-methyl D-aspartate 1; Grin2a, glutamate receptor ionotropic 
N-methyl D-aspartate 2A; Grm2, glutamate receptor metabotropic 2; Hba-a2, hemoglobin α adult chain 2; Hbb, hemoglobin β chain complex; Id2, inhibi-
tor of DNA binding 2; Slc1a3, glial high affinity glutamate transporter; Ptma, prothymosin α; Plp1, proteolipid protein 1.
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IUGR model, interfering in cell migration, axonal guidance, 
or neurite outgrowth. Some of them are of particular inter-
est, such as Plxna2 (a semaphorin receptor), Map1b (a micro-
tubule bundle formation molecule), Dpysl3 (a key player in 
axonal growth), Gsk3b (a kinase mediating neurogenesis and 
neuronal polarization), Lsamp (a recognition molecule for 
the formation of limbic connections), Prkce (a kinase with 
a role in neurite outgrowth and presynaptic regulation), Nfix 
(a transcription factor required for neural stem cell homeo-
stasis), and Crim1 (a growth factor binding transmembrane 
protein). Conversely, the highest upregulated transcripts 
in the DEX-IUGR hippocampus were the iron-containing 
oxygen-transport metalloproteins (Hba-a2 and Hbb). This 
 “ectopic” expression, out of red blood cells, corroborates 
recent neuronal hemoglobin detection with an oxygen capac-
itator activity (38).
It was also interesting to note that some transcripts of interest 
were upregulated in control pups born to  bLf-supplemented 
dams, such as Ttr (a transport protein for retinol-binding 
protein/thyroxine, widely used as a clinical nutritional 
marker), Plp1 (a protein associated with myelin biogenesis/
compaction), Metrn (a neurotrophic factor), Ptma (a necro-
sis inhibitor) and Clu (a glycoprotein chaperone molecule). 
This transcriptional effect of maternal bLf-supply in normal 
conditions was associated with increased levels of NAA and 
pools of NAA+NAAG and Cr+PCr. Other transcripts were 
specifically upregulated by maternal bLf exclusively in DEX-
IUGR pups, such as Nrep (neuronal regeneration related pro-
tein) and S100b (a marker of the nervous system damage at 
adulthood with neurotrophic function in the developping 
central nervous system and shown as decreased following 
prenatal stress) (39).
We observed no difference in maternal red blood cell, Hb, 
or hematocrit levels in response to bLf supply, as previously 
reported after long-term delivery of 200–2,000 mg bLf/kg/d (40) 
or 1,800 mg recombinant human apo-Lf/kg/d (41) in adult rats. 
Together, these results confirm that the bLf supplementation 
does not interfere with maternal hematocrit during normal iron 
availability in rats in contrast to its antianemic action described 
in recent clinical studies (42). Benefits of maternal bLf supple-
mentation on DEX pups do not appear to be directly mediated 
by an improved maternal iron metabolism. However, hippo-
campal gene expression of DMT-1 (a cellular iron/metal trans-
porter from the plasma membrane to endosomes), decreased in 
IUGR pups was restored with maternal bLf-supply, suggesting 
that more investigations in the field of pup hippocampal iron 
metabolism are required. DMT-1 is expressed in various cerebral 
cell types suggesting an important role in metal homeostasis in 
the brain (43). Moreover, a specific knock-out mouse model has 
shown that neuronal iron uptake by DMT-1 is essential for nor-
mal hippocampal neuronal development (44). Iron availability 
was shown to impact the neurochemical profile, apical dendritic 
growth, maturation of synaptic function, and gene expression in 
the developing hippocampus (for review, see ref. 45).
Taken together, our present observations demonstrate 
for the first time that maternal supplementation with bLf 
stimulates fetal growth in normal gestation and allows DEX-
induced IUGR pups to catch-up during the lactating period. 
Hippocampal altered metabolites and gene expression are 
hallmarks of DEX-induced IUGR changes. These alterations 
may indicate defective hippocampal development resulting in 
later cognitive impairment. In reversing several of the DEX-
induced IUGR sequelae, maternal bLf supplementation could 
be viewed as a promising nutritional intervention for early 
neuroprotection and growth support.
METHODS
Animal Care and Diets
All experimental protocols were approved by the State of Geneva 
Veterinary Office (Geneva, Switzerland). Pregnant Sprague Dawley 
OFA rat dams (Charles River Laboratories, L’Arbresle, France) were 
housed individually under standard conditions (Faculty of Medicine, 
Geneva University) with free access to either normal or bLf-enriched 
diet. Both diets, strictly isocaloric and prepared in Nestlé Research 
Center (Vers-chez-les-Blanc, Switzerland), contain 52% corn-
starch, 10% sucrose, 7% soybean oil, 5% cellulose, 3.5% mineral mix 
AIN-93G, 1% vitamin mix AIN-93, 0.25% choline bitartrate, 0.3% 
L-cystine, and 0.0014% Tert-butylhydroquinone. Control diet con-
tains 20.85% casein whereas bLf-enriched diet contains 20% casein 
and 0.85% bLf. Iron content in bLf supply is 120 ppm, representing 
a negligeable contribution to whole food iron content. Estimated bLf 
consumption ranges from ~500 mg (during gestation) to 1,300 mg 
(during lactation) bLf/kg of body weight. Weight and food intake of 
dams were monitored weekly during gestation and pups weights were 
monitored weekly until weaning. At PND1, litter size was brought to 
10–12 pups per dam to avoid any confounding litter size effect.
DEX Exposure
Control and bLf-fed dams were implanted subcutaneously with an 
Alzet osmotic minipump (Charles River Laboratories) delivering 
either vehicle or dexamethasone at the dose of 100 μg/kg/d (Sigma-
Aldrich, Buchs, Switzerland) from gestational day 14 to 21.
Hematological Measurements
Maternal blood was collected in EDTA-coated tubes on G0 (just 
before food group assignation), on G14 (2 wk after initiation of bLf-
enriched or normal diet consumption), and on G21 (after 1 wk of 
subcutaneous dexamethasone or vehicle exposure). Hematological 
values were obtained using an automated hematology analyzer KX-21 
(Sysmex Europe, Norderstedt, Deutschland).
In Vivo 1H NMR Spectroscopy
In vivo 1H MRS was performed on PND7 pups under isoflurane (1.5–
2%) using a 9.4T/31 cm magnet (Magnex Scientific, Abington, UK; 
Varian, Palo Alto, CA) equipped with 12-cm gradient coils (400 mT/m, 
120 µs). A transceive 17-mm-diameter 1H quadrature surface coil was 
used. A voxel of interest (1.5 × 2.5 × 2.5 mm3) was placed in the hip-
pocampus. First- and second-order shims were adjusted using fast 
automatic shimming technique by mapping along projections. Spectra 
were acquired using an ultra-short echo time SPECIAL spectroscopy 
method with TE/TR = 2.7/4,000 ms and 30 blocks of 16 averages. 
The metabolite concentrations were quantified using LCModel. The 
water spectra were used as reference assuming cerebral water content 
of 87.8% at PND7. The results provided the quantification of the fol-
lowing 17 metabolite concentrations in the hippocampus: macromol-
ecules, ascorbate, β-hydroxybutyrate, phosphorylcholine, creatine, 
phosphocreatine, γ-aminobutyric acid, glucose, glutamate, glutamine, 
myoinositol, lactate, N-acetylaspartate, N-acetylaspartylglutamate, 
phosphocreatine, phosphoethanolamine, and taurine.
Microarray Analysis
At PND7, the hippocampus from 10 pups originating from three 
independent litters for each group were carefully dissected, fro-
zen in liquid nitrogen, and stored at −80 °C before being disrupted 
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and homogenized in lysis buffer using FastPrep instrument/lysing 
tubes containing ceramic beads (MP Biomedicals Europe, Illkirch, 
France). Total RNA was then extracted, purified with the RNAdvance 
Agencourt tissue kit (Beckman Coulter, Nyon, Switzerland) with a 
Hamilton robotic station (Hamilton, Bonaduz, Switzerland). RNA 
was quantified with the RiboGreen RNA Quantification Kit (MP 
Biomedicals Europe) and monitored for quality on an Agilent 2100 
Bioanalyser (Agilent Technologies, Morges, Switzerland). cRNA 
targets were synthesized, labeled, and purified according to the 
Illumina TotalPrep RNA amplification protocol (Illumina, San Diego, 
CA). Hybridization mix was applied to each microarray (RatRef-12 
Expression BeadChips; Illumina). After hybridization (16 h, 58 °C), 
the microarrays were washed, stained with Streptavidin-Cy3 and 
scanned with a BeadArray Reader (Illumina). Signal intensities were 
extracted and summarized in the GenomeStudio software (Illumina). 
Data were expressed as absolute intensities. Quality control of the 
data was performed on all samples with a Pearson correlation matrix 
and a principal component analysis. After log2 transformation, data 
were quantile normalized and analyzed by ANOVA, followed by a 
Global Error Assessment. Gene expression changes greater than 20% 
with a P value < 0.001 were considered as biologically relevant and 
statistically significant.
Real-Time Quantitative PCR
Two micrograms of total RNA were reverse transcribed using 400 units 
of Moloney murine leukemia virus reverse transcriptase (Invitrogen, 
Basel, Switzerland), 1 unit/µl RNAsin (Promega, Madison, WI), 0.2 µg 
of random primers (oligo(dN)6) (Promega), 2 mmol/l dNTP, and 
20 µmol/l of dithiothreitol (Invitrogen). Gene expression of the cDNAs 
of interest was determined by real-time quantitative PCR using an 
ABI StepOne Plus Sequence Detection System (Applera Europe, 
Rotkreuz, Switzerland) and were normalized using the housekeeping 
gene RPS29 or tubulin. List of primers is provided in Table 4.
Histology
At PND7, pups were anesthetized, perfused intracardially with 0.9% 
NaCl and then with 4% paraformaldehyde. Brains were removed, 
postfixed in 4% paraformaldehyde overnight, then 30% sucrose for 
24 h and stored at −80°C. Ten micrometer sections at the level of the 
hippocampus were classically cut on a cryostat before being blocked 
with 4% BSA (Sigma-Aldrich), then with 0.3% Triton/PBS 1X for 
60 min and incubated with 4′-6-diamidino-2-phenylindole. Digital 
images were obtained using a microscope coupled with a camera 
AxioCam MRc5 controlled by Axiovision AC software (Carl Zeiss 
MicroImaging GmbH, Germany).
Statistics
Animals originated from at least three independent litters in each 
group for each endpoint investigated to account for the intragroup 
variability between litters. Results are expressed as mean ± SEM. 
We performed the unpaired Student’s t-test and repeated-measures 
one-way ANOVA. We considered a P value of < 0.05 as statistically 
significant.
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